2021年12月18日，中國中藥(yao)(yao)協會四屆五(wu)次理事會在京召開。會議(yi)期間，以網絡直播(bo)方式隆重發布2021年度中藥(yao)(yao)產(chan)業信息，九芝堂疏血通注(zhu)射(she)液、六味地黃丸、天麻鉤藤顆粒榮登臨(lin)床(chuang)價值中成藥(yao)(yao)品牌(pai)榜，九芝堂股份(fen)有限(xian)公司榮登中成藥(yao)(yao)企(qi)業TOP100榜單，位列(lie)第26位！

本次臨(lin)床價值中(zhong)(zhong)(zhong)(zhong)(zhong)成(cheng)藥(yao)(yao)品(pin)(pin)牌(pai)(pai)榜評(ping)選以臨(lin)床價值為導向，依據協會(hui)發布的《中(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)品(pin)(pin)牌(pai)(pai)評(ping)價 通則(ze)》、《中(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)品(pin)(pin)牌(pai)(pai)評(ping)價 中(zhong)(zhong)(zhong)(zhong)(zhong)成(cheng)藥(yao)(yao)》、《中(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)品(pin)(pin)牌(pai)(pai)評(ping)價 中(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)飲片》團體標準共識中(zhong)(zhong)(zhong)(zhong)(zhong)推(tui)(tui)薦治(zhi)療(liao)中(zhong)(zhong)(zhong)(zhong)(zhong)醫優勢病種的中(zhong)(zhong)(zhong)(zhong)(zhong)成(cheng)藥(yao)(yao)，結合各省(sheng)行業協會(hui)推(tui)(tui)薦和品(pin)(pin)牌(pai)(pai)專家組主動研究(jiu)，確定臨(lin)床價值高(gao)、循證證據充分、臨(lin)床主動功能獨(du)特、品(pin)(pin)牌(pai)(pai)影(ying)響力強的中(zhong)(zhong)(zhong)(zhong)(zhong)成(cheng)藥(yao)(yao)及經(jing)典名方進入(ru)遴選范圍，并堅持(chi)負面清單一(yi)票否決(jue)原則(ze)。

天(tian)麻鉤藤顆粒、疏血(xue)通(tong)注射液、六味(wei)地黃丸位列榜單，既充分(fen)彰顯(xian)了(le)九芝(zhi)堂中成藥產品臨床價(jia)值，又有助于九芝(zhi)堂品牌影響力提升！

中(zhong)(zhong)成藥(yao)(yao)企(qi)業(ye)TOP100榜(bang)單(dan)是(shi)通過企(qi)業(ye)產(chan)品信(xin)息(xi)征集、信(xin)息(xi)檢索和品牌專(zhuan)家組主動(dong)研究，參(can)考工信(xin)部發(fa)布(bu)(bu)的(de)醫藥(yao)(yao)統(tong)計(ji)年報百強(qiang)企(qi)業(ye)，醫藥(yao)(yao)上市公司(si)統(tong)計(ji)年報數據，各新(xin)聞媒(mei)體和咨詢(xun)公司(si)發(fa)布(bu)(bu)的(de)行(xing)業(ye)排行(xing)榜(bang)，中(zhong)(zhong)成藥(yao)(yao)企(qi)業(ye)上報信(xin)息(xi)，中(zhong)(zhong)藥(yao)(yao)行(xing)業(ye)大型分析報告中(zhong)(zhong)的(de)相關(guan)信(xin)息(xi)，協(xie)會(hui)會(hui)員(yuan)單(dan)位基礎信(xin)息(xi)，協(xie)會(hui)承擔課題中(zhong)(zhong)的(de)相關(guan)信(xin)息(xi)，并(bing)依(yi)據企(qi)業(ye)主營(ying)業(ye)務收入、企(qi)業(ye)研發(fa)創新(xin)情況(kuang)，堅持負(fu)面清單(dan)一票否決原則而產(chan)生(sheng)。九(jiu)芝(zhi)堂(tang)榮耀上榜(bang)，是(shi)對九(jiu)芝(zhi)堂(tang)綜合(he)實力、社會(hui)影響力的(de)充分肯(ken)定！

值得一(yi)提(ti)的是，會上，中(zhong)(zhong)國醫學院科學植(zhi)物藥(yao)用研(yan)(yan)(yan)究(jiu)所孫曉波(bo)所長作(zuo)《2021年度臨床(chuang)價值中(zhong)(zhong)成藥(yao)品牌(pai)榜樣遴選基本情況匯報》，以(yi)九芝堂“疏(shu)(shu)(shu)血(xue)通(tong)(tong)(tong)(tong)注射(she)液(ye)(ye)”為例(li)，向(xiang)參會人員介紹(shao)了(le)中(zhong)(zhong)藥(yao)注射(she)劑可(ke)(ke)評價，能(neng)夠(gou)得到同(tong)行、尤其西(xi)醫的認(ren)(ren)可(ke)(ke)。孫教(jiao)授提(ti)到，疏(shu)(shu)(shu)血(xue)通(tong)(tong)(tong)(tong)注射(she)液(ye)(ye)SPACE研(yan)(yan)(yan)究(jiu)完全以(yi)西(xi)醫單位為主(zhu)認(ren)(ren)定，充(chong)分肯定了(le)產品療(liao)效(xiao)，急性(xing)(xing)期給與(yu)疏(shu)(shu)(shu)血(xue)通(tong)(tong)(tong)(tong)注射(she)液(ye)(ye)可(ke)(ke)以(yi)顯著(zhu)降低患者15%的復(fu)發風險(xian)，且不增加出血(xue)等安(an)全性(xing)(xing)風險(xian)。同(tong)時疏(shu)(shu)(shu)血(xue)通(tong)(tong)(tong)(tong)注射(she)液(ye)(ye)能(neng)量代謝、新增血(xue)管(guan)、改善循(xun)環作(zuo)用機理基礎(chu)性(xing)(xing)研(yan)(yan)(yan)究(jiu)扎實；進一(yi)步研(yan)(yan)(yan)究(jiu)通(tong)(tong)(tong)(tong)過Meta分析，以(yi)大量文獻證明了(le)產品療(liao)效(xiao)；在(zai)安(an)全性(xing)(xing)、有效(xiao)性(xing)(xing)、經濟性(xing)(xing)方面也(ye)得到了(le)充(chong)分的肯定。孫教(jiao)授指出，這項研(yan)(yan)(yan)究(jiu)未來會推動中(zhong)(zhong)成藥(yao)臨床(chuang)品牌(pai)價值設立(li)。

進入新發(fa)(fa)展(zhan)(zhan)(zhan)階(jie)段，尤其疫情以(yi)來，中醫(yi)(yi)藥(yao)迎(ying)來了前所未有(you)的戰(zhan)略機遇期。九芝堂作(zuo)為中華老(lao)字號企業(ye)、中醫(yi)(yi)藥(yao)文化典型代表，以(yi)“在傳承(cheng)中創(chuang)新，在創(chuang)新中發(fa)(fa)展(zhan)(zhan)(zhan)”為發(fa)(fa)展(zhan)(zhan)(zhan)理念，一直致(zhi)力(li)于傳承(cheng)好(hao)、發(fa)(fa)展(zhan)(zhan)(zhan)好(hao)中醫(yi)(yi)藥(yao)事業(ye)，為建設(she)健康中國(guo)貢獻力(li)量(liang)！